<DOC>
	<DOCNO>NCT02459899</DOCNO>
	<brief_summary>The primary objective study define dose lead desirable efficacy , measure change hemoglobin A1C ( A1C ) Baseline Week 12 .</brief_summary>
	<brief_title>Dose-ranging Study Patients With Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Patient give write informed consent participate study accordance local regulation Adult patient 18 year old diagnosis T1D make least 1 year prior informed consent Patients treat insulin insulin analog deliver via CSII MDI At Screening Visit , A1C must 7.0 % 10.0 % Females childbearing potential must use adequate method contraception negative pregnancy test Use antidiabetic agent insulin insulin analog time screen Use sodiumglucose cotransporter ( SGLT ) inhibitor within 8 week prior screen Chronic systemic corticosteroid use Type 2 diabetes mellitus ( T2DM ) , severely uncontrolled T1D determine Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>